Verb Biotics products

Our first-in-class keystone single-strain biotherapies address the root causes of the disease by regenerating a healthy microbiome, with subsequent deep beneficial effect on patients.

Yso4 is an exploratory program targeting the gut-brain axis for the treatment of mood disorders. Over the last 5 years, there has been increasing evidence that the gut microbiome was associated with neurological and behavioral disorders, which led to the so called “gut-brain axis” concept.

Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down disease progression. Discover the articles we published in Scientific Reports: Relizani et al. 2022 and Kropp et al. 2021. Our team has selected from our proprietary strain library a lead candidate with high anti-inflammatory potential and protective action on gut epithelium.

Yso3 is a preclinical drug development program aimed at treating asthma. Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with developing this new biotherapy. Continue our development plan to the clinical phase is the further step for this program.

Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key functions.